Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Johannes Waltenberger,
Epigenetics relates to changes in gene expression that do not involve changes in gene sequences. In recent years, three mechanisms of epigenetic modifications have been identified: 1) DNA methylation, 2) Histone modifications, 3) Non-coding small RNAs. In addition, it is interesting to note that such changes can occur rather fast. During a very interesting symposium at the ESC congress in Stockholm, Dr. M.E. Symonds from Nottingham, GB, highlighted the relation between low birth-weight, e.g. secondary to maternal nutrient restriction, and obesity and insulin resistance of the offspring resulting in a higher cardiovascular mortality. This aspect was further elucidated by Dr. R. Gemke from Amsterdam, NL. Dr. S. Yla-Herttuala from Kuopio, FI, presented interesting insights into the role of epigenetics in the pathogenesis of atherosclerosis. He demonstrated that hypomethylation is present in atherosclerotic plaques at a magnitude otherwise seen in malignant tumors. This hypomethylation is relevant as it is associated with enhanced proliferation secondary to increased transcriptional activity. Likewise, the activity of the angiogenic factor VEGF is controlled and facilitated by small RNA species such as siRNA and shRNA. Besides atherosclerosis, other cardiovascular conditions including heart failure and thrombophilia are partly controlled by epigenetic mechanisms, as Dr. R. Foo from Cambridge, UK, pointed out in his presentation. It is important to note that these mechanisms may even be influenced by therapeutic interventions. One such example is the use of folic acid, which may influence methylation and thereby control or modifiy gene expression to treat cardiac and vascular diseases.
Epigenetics of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved